Portland, OR — (PRESS RELEASE JET) — 10/25/2017 — PEGylation refers to the process of amalgamation or attachment of polyethylene glycol (PEG) polymer chains with macromolecules such as drug molecule, therapeutic protein, or vesicles by covalent bonding. PEGylation offers a broad range of advantages such as improved drug solubility, reduced dosage frequency, and increased drug stability increases the demand for the market.
The factors that propel the market growth include high prevalence of chronic diseases such as cancer, kidney diseases, and rheumatoid arthritis, due to lifestyle changes, increase of protein stability and half-life, and rise in implementation of protein-based drugs as compared to non-protein ones.
Get the sample copy of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3726
The global PEGylated protein market is segmented on the basis of product, protein type, application, end user, and region. Based on product, it is divided into consumables and services. According to the protein type, the market is classified into colony stimulating factors, erythropoietin, mAb, interferons, and recombinant factor VIII. On the basis of application, the market is categorized into cancer treatment, chronic kidney diseases, hepatitis, multiple sclerosis, hemophilia, and gastrointestinal disorders.
Make a purchase enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3726
Key players profiled in the report include Thermo Fisher Scientific Inc., Merck KGaA, JenKem Technology USA, Creative PEGWorks, NOF Corporation, Biometrics Research Group, Inc., Quanta BioDesign, Ltd., Iris Biotech GmbH, Laysan Bio, Inc., and Genzyme Corporation.
Pegylated Proteins Market Key Segments:
By Protein Type
-Colony Stimulating Factors
-Monoclonal Antibodies (mAbs)
-Recombinant Factor VIII
-Chronic Kidney Diseases
By End User
-Contract Research Organizations (CROs)
-Pharmaceutical & Biotechnology Companies
-Academic Research Institutes
Powered by WPeMatico